Closed-system process optimization for CGT manufacturing and storage

The manufacture of cell and gene therapies (CGTs) faces persistent cost, quality, and contamination challenges from open, manual processing and uncontrolled storage. Transitioning to closed-system manufacturing and cryostorage has been shown to reduce batch failures threefold and manufacturing costs by up to 45%, while tripling throughput and maintaining cell viability. This article summarizes comparative data and case studies demonstrating how process closure supports scalable, contamination-resistant, and economically viable CGT production.

Please enter your email to access content Read now